Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) Equity Average (2018 - 2025)

Historic Equity Average for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $25.3 million.

  • Precision Biosciences' Equity Average fell 6368.53% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 6368.53%. This contributed to the annual value of $37.6 million for FY2024, which is 509.5% down from last year.
  • According to the latest figures from Q3 2025, Precision Biosciences' Equity Average is $25.3 million, which was down 6368.53% from $41.7 million recorded in Q2 2025.
  • Precision Biosciences' 5-year Equity Average high stood at $101.0 million for Q3 2021, and its period low was $24.0 million during Q4 2023.
  • Its 5-year average for Equity Average is $59.9 million, with a median of $56.0 million in 2024.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 6690.63% in 2023, then surged by 15302.35% in 2024.
  • Quarter analysis of 5 years shows Precision Biosciences' Equity Average stood at $96.3 million in 2021, then decreased by 24.82% to $72.4 million in 2022, then tumbled by 66.91% to $24.0 million in 2023, then soared by 153.02% to $60.6 million in 2024, then tumbled by 58.2% to $25.3 million in 2025.
  • Its Equity Average was $25.3 million in Q3 2025, compared to $41.7 million in Q2 2025 and $52.9 million in Q1 2025.